Showing 1–20 of 34 results

Show sidebar

Antibody-Drug Conjugates (ADCs) are cancer treatments that combine antibodies with powerful chemotherapy drugs. The antibody targets specific cancer cell markers, guiding the attached drug directly to the tumor. This approach allows the drug to focus on the cancer cells, minimizing harm to healthy tissue and reducing side effects. ADCs are used in treating a variety of cancers, such as breast cancer, lung cancer, and urothelial cancer.

Antibody-Drug Conjugates

Cat# Name Structure M.W. Purity Pricing
AP15354Sacituzumab govitecan (solution)842.89≥97% Pricing
AP15529Loncastuximab tesirine≥99% Pricing
AP15538Trastuzumab deruxtecan153000 (average)≥95% Pricing
AP15539Sacituzumab govitecan≥98% Pricing
AP15540Trastuzumab deruxtecan (solution)≥99% Pricing
AP15541Trastuzumab emtansine≥98% Pricing
AP15542Datopotamab deruxtecan149000 (average)≥95% Pricing
AP15543ADC Control Human IgG1-Deruxtecan (DAR 4)≥95% Pricing
AP15544Ifinatamab deruxtecan≥95% Pricing
AP15545ADC Control Human IgG1-Deruxtecan (DAR 8)≥95% Pricing
AP15546Disitamab vedotin149000 (average)≥98% Pricing
AP15547Mirvetuximab soravtansine (solution)150000 (average)≥95% Pricing
AP15548Patritumab deruxtecan158000 (average)≥99% Pricing
AP15549Enfortumab vedotin-ejfv (solution)≥99% Pricing
AP15551Belantamab mafodotin≥99% Pricing
AP15552Enfortumab vedotin-ejfv≥99% Pricing
AP15553Telisotuzumab vedotin≥99% Pricing
AP15554Gemtuzumab ozogamicin≥98% Pricing
AP15555Brentuximab vedotin (solution)≥99% Pricing
AP15556Tusamitamab ravtansine148000 (average)≥99% Pricing
AP15557Trastuzumab emtansine (solution)≥95% Pricing
AP15558Polatuzumab vedotin≥98% Pricing
AP15550Tisotumab vedotin152000 (average)≥95% Pricing
AP15307Farletuzumab ecteribulin149000 (average)≥97% Pricing
AP14757Glembatumumab vedotin≥99% Pricing
AP14558Trastuzumab duocarmazine≥99% Pricing
AP14447Zilovertamab vedotin≥98% Pricing
AP13788Cofetuzumab pelidotin≥99% Pricing
AP13744Cantuzumab ravtansine≥98% Pricing
AP13701Depatuxizumab mafodotin148,251.25≥95% Pricing
AP13651ORM-5029≥99% Pricing
AP13616Depatuxizumab MMAE148000 (average)≥95% Pricing
AP13434ADC Control Human IgG1-vcMMAF≥95% Pricing
AP15462Labetuzumab govitecan154K≥95% Pricing

Bulk Inquiry


    Antibody-Drug Conjugates (ADCs)

    Antibody-Drug Conjugates (ADCs) are innovative cancer treatments that combine monoclonal antibodies with powerful chemotherapy drugs. The antibody targets specific markers on cancer cells, guiding the attached drug directly to the tumor. This method allows the drug to act more precisely on cancer cells, reducing damage to healthy tissue and minimizing side effects. ADCs are being used to treat cancers like breast cancer, lung cancer, and urothelial cancer.

    Key Features of ADCs:

    • Targeted delivery of chemotherapy to cancer cells
    • Monoclonal antibodies direct the drug to the tumor
    • Reduces side effects and systemic toxicity
    • Increases the effectiveness of cancer treatment
    • Used for a variety of cancers

    Common Applications of ADCs:

    1. Breast Cancer: Used for HER2-positive breast cancer patients, such as Trastuzumab emtansine (Kadcyla).
    2. Lung Cancer: Targeting lung cancers with specific markers, like TROP2 and EGFR.
    3. Urothelial Cancer: Effective for advanced or metastatic urothelial carcinoma, such as Enfortumab vedotin (Padcev).
    4. Gastric Cancer: Investigated for HER2-positive gastric cancer treatment.
    5. Other Cancers: ADCs are being explored for various cancers with specific targets.

    Notable ADCs:

    • Trastuzumab emtansine (Kadcyla): For HER2-positive breast cancer.
    • Enfortumab vedotin (Padcev): For metastatic urothelial cancer.
    • Sacituzumab govitecan (Trodelvy): For metastatic triple-negative breast cancer.
    • Disitamab vedotin (RC48): For various solid tumors.

    ADCs offer a more precise approach to cancer treatment, providing effective therapies with fewer side effects.